Management of Acute and Recurrent Pericarditis with Ibuprofen and Adjacent Therapies

Ibuprofen Dosing Regimens (European Society of Cardiology Guidelines)

• Acute pericarditis – initial therapy: Ibuprofen 600 mg orally every 8 hours (total 1 800 mg/day) for 1–2 weeks, guided by symptom resolution and C‑reactive protein (CRP) normalization.  [1][2]
• Acute pericarditis – tapering: Reduce the dose by 200–400 mg every 1–2 weeks once the patient is asymptomatic and CRP has normalized.  [1][2]
• Recurrent pericarditis – initial therapy: Ibuprofen 600 mg every 8 hours (total 1 200–2 400 mg/day) for a duration of several weeks to months, typically longer than in the first episode.  [3][4]
• Recurrent pericarditis – tapering: Same stepwise reduction (200–400 mg every 1–2 weeks) but may require several months of tapering in resistant cases.  [3][4]

Mandatory Adjunctive Therapy

Colchicine (Class I, Level A)

• Dose: 0.5 mg once daily for patients < 70 kg; 0.5 mg twice daily for patients ≥ 70 kg.  [1][2]
• Duration: 3 months for acute pericarditis; at least 6 months for recurrent pericarditis.  [1][4]
• Efficacy: Halves the recurrence rate (from ≈ 30–50 % to ≈ 15–30 %).  [1][5]

Gastro‑protection

• Requirement: A proton‑pump inhibitor or H₂‑blocker must be co‑prescribed with any NSAID regimen.  [1][2]

Monitoring Parameters

• CRP: Serial CRP measurements should dictate the length of therapy and timing of tapering.  [1][2]
• Tapering rule: Dose reduction is permitted only when the patient is symptom‑free and CRP is within normal limits.  [3][5]
• Cardiac imaging: Repeat ECG and transthoracic echocardiography to confirm resolution of inflammatory changes.  [1][2]

Contra‑indications to Ibuprofen

• Absolute: Documented NSAID allergy, recent peptic ulcer or active gastrointestinal bleeding, and use of oral anticoagulants with high bleeding risk.  [4][6]
• Relative (CAD): In patients with coronary artery disease, aspirin 750–1 000 mg every 8 hours is preferred because of its antiplatelet effect.  1

Alternative/Second‑Line Therapies

Corticosteroids

• Indication: Reserved for cases where NSAIDs and colchicine are contraindicated or have failed, or for specific conditions (autoimmune disease, post‑pericardiotomy syndrome, pregnancy).  [1][4]
• Dose: Low‑to‑moderate prednisone 0.2–0.5 mg/kg/day (avoid high‑dose 1 mg/kg/day).  [1][4]
• Risk: Increases recurrence rates up to ≈ 50 % and promotes chronic disease; therefore, should not be used as first‑line therapy.  [1][2]3
• Tapering: When prednisone reaches 10–15 mg/day, decrement by 1.25–2.5 mg every 2–6 weeks.  [3][7]

Aspirin

• Dose: 750–1 000 mg orally every 8 hours; preferred in patients with CAD, heart‑failure, or when antiplatelet therapy is already indicated.  1

Indomethacin

• Dose: 25–50 mg orally every 8 hours; associated with higher central‑nervous‑system adverse effects and not available over‑the‑counter in the United States.  3

Common Pitfalls & Corrective Strategies

• Inadequate initial treatment (premature taper or insufficient duration) is the leading cause of recurrence; maintain full‑dose ibuprofen until both symptoms and CRP have normalized.  [3][1]3
• Premature corticosteroid use raises recurrence from 15–30 % to ≈ 50 %; reserve steroids for true NSAID/colchicine failure.  [2][3][1][4]
• Shortened colchicine course (stopping before 3 months for acute or 6 months for recurrent) markedly increases recurrence risk.  [1][4]5
• Infection exclusion: Bacterial and tuberculous pericarditis must be ruled out before initiating corticosteroids.  [4][6]

Exercise Recommendations

• Non‑athletes: Suspend physical activity until symptoms resolve and CRP, ECG, and echocardiogram are all normal.  [1][2]
• Athletes: Minimum 3‑month restriction from competitive sport, ensuring complete normalization of clinical and imaging parameters.  [1][2]

Steroid Tapering and Recurrence Prevention in Tuberculous Pericarditis

Tapering Protocol and Recurrence Risk

• When the prednisone dose reaches 10–15 mg/day, the taper should be slowed to reductions of 1.25–2.5 mg every 2–6 weeks to minimise rebound inflammation and prevent recurrence of pericardial disease – recommendation based on European Society of Cardiology guidance (European Heart Journal 2015) 8.
• Abrupt discontinuation of corticosteroids is associated with rebound pericardial inflammation; therefore a gradual taper is essential – supported by the same ESC evidence (European Heart Journal 2015) 8.

Natural History Without Steroid Therapy

• In the absence of adjunctive corticosteroids, 20–30 % of patients with tuberculous pericarditis develop constrictive pericarditis, highlighting the morbidity risk that steroids aim to mitigate (European Heart Journal 2015) 8.

Diagnostic Precautions Before Initiating Steroids

• Bacterial (purulent) pericarditis must be excluded prior to starting corticosteroid therapy, because steroids would be harmful in this setting (European Heart Journal 2015) 8.

Evidence Strength

• The above recommendations are derived from expert consensus and observational data reported in a 2015 European Heart Journal article; no randomized controlled trial directly addresses the optimal tapering schedule, so the evidence is considered moderate (expert opinion/observational).